US OptionsDetailed Quotes

AGEN241018C2000

Watchlist
  • 0.00
  • 0.000.00%
15min DelayClose Sep 27 09:30 ET
0.00High0.00Low
Intraday
  • 5D
  • Daily

No Data

News

Comments

    Jaguar8
    Jaguar8
    Sep 13 10:46
    NEWS
    $Agenus (AGEN.US)$
    Botensilimab/Balstilimab Clinical Responses in Refractory Sarcomas Presented at ESMO 2024
    Agenus Inc. (Nasdaq: AGEN) presented promising data at the ESMO Congress for their Phase 1 study of botensilimab (BOT) and balstilimab (BAL) combination in refractory sarcomas. Key findings include:
    - 23% overall response rate (ORR) in the full sarcoma cohort
    - 21.7 months median duration of response (DOR)
    - 69% 12-month overall survival (OS)
    - 39% ORR in angiosarcoma subtype
    - Managea...
    Trytosaveabit
    Trytosaveabit
    Sep 9 14:14
    Hehehe! They going to fudge the results at today’s conference?
    $Agenus (AGEN.US)$ Agenus Sued by Shareholder for Misleading Investors Over Colorectal Cancer Immuno-Therapy Trial Results
    MT Newswires· 10 mins ago
    Agenus (AGEN) is being accused of misleading investors in public comments about a combination of two prospective treatments for cancer in a new shareholder suit filed last week in federal court in Massachusetts.
    The Boston-area biotech company has been working to develop several new immuno...
    4
    Jaguar8
    Jaguar8
    Sep 9 06:34
    NEWS
    $Agenus (AGEN.US)$
    Botensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to be Presented in Oral Session at ESMO 2024
    Agenus Inc. (Nasdaq: AGEN) announced that updated data from the clinical trial of botensilimab and balstilimab in refractory sarcomas will be presented at the ESMO Congress 2024 in Barcelona. The presentation will showcase updated efficacy and safety data from the ongoing Phase 1 trial, highlighting the potential of this combination therapy in treating patients wit...
    Jaguar8
    Jaguar8
    Aug 7 10:03
    NEWS
    $Agenus (AGEN.US)$
    Agenus Publishes Seminal Study on Botensilimab’s Activity in Treatment-Resistant Cancers
    Agenus Inc. (NASDAQ: AGEN) has published a groundbreaking study in Cancer Discovery on botensilimab, their novel Fc-enhanced anti-CTLA-4 antibody. The study highlights botensilimab's effectiveness against treatment-resistant cancers, including those unresponsive to conventional immunotherapy. Key findings include:
    1. Demonstrated activity across multiple cancer types
    2. Unique Fc-enhanc...
Read more